




Supplementary Figure S1. Digital images of Stage II cultured cells taken 4 hours after activation with LPS and ODN1826 taken with 20x objective using Zeiss Primovert microscope equipped with an Axiocam model 105 color-capable digital camera.



Supplementary Figure S2. Flow cytometry analysis of Stage II DC that completed stage I culture in various serum-free media (expressed as histograms). Stage II cultured DC were activated with a combination of ODN1826 and LPS, harvested and stained 24h later with fluorochrome-conjugated antibodies against I-A^d, CD11b, CD40, CD80 and CD86 (black traces). Gray traces represent isotype-matched controls. “FBS”, RPMI medium supplemented with 10% fetal calf serum; “HL-1”, RPMI medium supplemented with HL-1 serum substitute; “M-SFM”, Macrophage Serum-Free Medium; X-V20, X-Vivo 20 serum-free medium.



Supplementary Figure S3. Representative IFN- γ ELISPOT images of stimulated immune splenocytes from individual mice. Splenocytes from mice vaccinated with SFM-DC pulsed with either egg ovalbumin class II peptide (OVA) or rat ErbB2/HER2 class I peptide (HER2) or from untreated mice (none) were stimulated with recall antigen (OVA, HER2 or no stimulation [None]) in a IFN- γ ELISPOT assay.



Supplemental Figure S4. Analysis of products secreted by cultured DCs. Supernatants from cultured activated Stage II murine SFM-DCs either treated with ODN1826 and LPS (activated) or left untreated (unactivated) were collected and analyzed via protein antibody array for the expression of 97 cytokines and chemokines associated with inflammation. Boxes indicate products produced at higher levels by activated DCs.

P1: ¹MIIMELAAWCRWGFLLALLP²⁰
 P2: ¹¹RWGFLLALLPPGIAGTQVCT³⁰
 P3: ²¹PGIAGTQVCTGTDMKRLRPA⁴⁰
 P4: ³¹GTDMKRLRPASPETHLDMRL⁵⁰
 P5: ⁴¹SPETHLDMRLHLYQGQCQVQ⁶⁰
 P6: ⁵¹HLYGQCQVQGNLELTYVPA⁷⁰
 P7: ⁶¹GNLELTYVPANASLSFLQDI⁸⁰
 P8: ⁷¹NASLSFLQDIQEVQGYMLIA⁹⁰
P9: ⁸¹QEVQGYMLIAHNQVKRVPLQ¹⁰⁰
 P10: ⁹¹HNQVKRVPLQRLRIVRG¹¹⁰
 P11: ¹⁰¹LRIVRG¹¹⁰TQLFEDKYALAVL¹²⁰
 P12: ¹¹¹FEDKYALAVLDNRDPQDNVA¹³⁰
 P13: ¹²¹DNRDPQDNVAASTPGRTP¹⁴⁰
 P14: ¹³¹ASTPGRTP¹⁴⁰EGRLRELQRLSL¹⁵⁰
 P15: ¹⁴¹LRELQRLSLTEILKGGVLR¹⁶⁰
 P16: ¹⁵¹EILKGGVLRGNPQLCYQDT¹⁷⁰
P17: ¹⁶¹GNPQLCYQDMVLWKDVFRKN¹⁸⁰
 P18: ¹⁷¹VLWKDVFRKNNQLAPVDIT¹⁹⁰
 P19: ¹⁸¹NQLAPVDITNRSRACPPCA²⁰⁰
 P20: ¹⁹¹NRSRACPPCAMCKDNHCWG²¹⁰
 P21: ²⁰¹PMCKDNHCWGESPEDCQILT²²⁰
 P22: ²¹¹ESPEDCQILGTICTSGCAR²³⁰
 P23: ²²¹GTICTSGCARCKGRLPTDCC²⁴⁰
 P24: ²³¹CKGRLPTDCCHEQCAAGCTG²⁵⁰
 P25: ²⁴¹HEQCAAGCTGPKHSDCLACL²⁶⁰
 P26: ²⁵¹PKHSDCLACLHFNHSGICEL²⁷⁰
 P27: ²⁶¹HFNHSGICELHCPALVTYNT²⁸⁰
 P28: ²⁷¹HCPALVTYNTDTFESMHNPE²⁹⁰

P29: ²⁸¹DTFESMHNPEGRYTFGASC³⁰⁰
 P30: ²⁹¹GRYTFGASCVTACPYNLYST³¹⁰
 P31: ³⁰¹TACPYNLYSTEVGSC³²⁰TLVCP
 P32: ³¹¹EVGSC³²⁰TLVCPNNQE³³⁰VTAE
 P33: ³²¹PNNQE³³⁰VTAE³⁴⁰GTQRCCKSK³⁵⁰
 P34: ³³¹GTQRCCKSKPCARVCYGLG³⁵⁰
P35: ³⁴¹PCARVCYGLGMEHLRGARAI³⁶⁰
 P36: ³⁵¹MEHLRGARAITSDNVQEF³⁷⁰DG
 P37: ³⁶¹TSDNVQEF³⁷⁰DGCKKIFGSLAF³⁸⁰
 P38: ³⁷¹CKKIFGSLAF³⁸⁰LPESFDGDP³⁹⁰
 P39: ³⁸¹LPESFDGDPSSGIAPLRPE⁴⁰⁰
 P40: ³⁹¹SGIAPLRPEQLQVFETLEE⁴¹⁰
 P41: ⁴⁰¹LQVFETLEEITGYLYISAWP⁴²⁰
 P42: ⁴¹¹TGYLYISAWPDSLRLDSV⁴³⁰
 P43: ⁴²¹DSLRLDSVFNLRIRGRIL⁴⁴⁰
 P44: ⁴³¹NLRIRGRILHDGAYSLTLQ⁴⁵⁰
 P45: ⁴⁴¹HDGAYSLTLQGLGIHSLGLR⁴⁶⁰
 P46: ⁴⁵¹GLGIHSLGLRLRELGSGLA⁴⁷⁰
 P47: ⁴⁶¹SLRELGSGLALIHNAHL⁴⁸⁰
P48: ⁴⁷¹LIHRNAHLCFVHTVPWDQLF⁴⁹⁰
 P49: ⁴⁸¹VHTVPWDQLFRNPHQALLH⁵⁰⁰
 P50: ⁴⁹¹RNPHQALLHSGNRPEEDCGL⁵¹⁰
 P51: ⁵⁰¹GNRPEEDCGL⁵¹⁰EGLVCNSLCA⁵²⁰
 P52: ⁵¹¹EGLVCNSLCAHGHWCWGP⁵³⁰
 P53: ⁵²¹HGHWCWGPQTQCVNCSHFLR⁵⁴⁰
 P54: ⁵³¹QCVNCSHFLRGQECVEECRV⁵⁵⁰
 P55: ⁵⁴¹GQECVEECRVWKGLPREYVS⁵⁶⁰
 P56: ⁵⁵¹WKGLPREYVSDKRCLPCHPE⁵⁷⁰

P57: ⁵⁶¹DKRCLPCHPEQCQPQNSSETC⁵⁸⁰
 P58: ⁵⁷¹CQPQNSSETCFGSEADQCAA⁵⁹⁰
 P59: ⁵⁸¹FGSEADQCAACAHAHYKSSSC⁶⁰⁰
 P60: ⁵⁹¹CAHYKSSSCVARCP⁶¹⁰SGVKP
 P61: ⁶⁰¹VARCP⁶¹⁰SGVKPDL⁶²⁰SYMPIWKY
 P62: ⁶¹¹DLSYMPIWKYPDEEGICQPC⁶³⁰

Supplemental Figure S5. Sequences of all peptides in rat HER2 overlapping peptide library. A peptide library was constructed based on the extracellular domain sequence of rat ErbB2/HER2. It consisted of 62 peptide 20-mers overlapping by 10 amino acids each. Underlined peptides (P9, p17, p35 and p48) were the four focused on in main studies.